Conversely, considering the relevance of promoter acetylation that is vital for the R280K p53 mutant to bind the DNA, inhibition of Ep300 may be considered as an alternative treatment against cancers possessing the p53 mutation, by hampering promoter acetylation and thus mutant p53 binding to the target promoters. The gene discussed is TP53; the disease is cancer.